Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Antitumor Activity of SSS59 in Advanced Malignant Tumors
NCT06944444Phase 1Recruiting
- Sponsor
- 3SBio
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of SSS59 in advanced malignant solid tumor, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (4 arms), sponsored by 3SBio. Primary endpoints: Dose-Limiting Toxicities at 21 days, Safety and tolerability and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
SSS59
03
Conditions
advanced malignant solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06944444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06944444.